Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Increasing fatty acid oxidation remodels the hypothalamic neurometabolome to mitigate stress and inflammation.

McFadden JW, Aja S, Li Q, Bandaru VV, Kim EK, Haughey NJ, Kuhajda FP, Ronnett GV.

PLoS One. 2014 Dec 26;9(12):e115642. doi: 10.1371/journal.pone.0115642. eCollection 2014.

2.

Pharmacological glycerol-3-phosphate acyltransferase inhibition decreases food intake and adiposity and increases insulin sensitivity in diet-induced obesity.

Kuhajda FP, Aja S, Tu Y, Han WF, Medghalchi SM, El Meskini R, Landree LE, Peterson JM, Daniels K, Wong K, Wydysh EA, Townsend CA, Ronnett GV.

Am J Physiol Regul Integr Comp Physiol. 2011 Jul;301(1):R116-30. doi: 10.1152/ajpregu.00147.2011. Epub 2011 Apr 13.

3.

Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas.

Ueda SM, Yap KL, Davidson B, Tian Y, Murthy V, Wang TL, Visvanathan K, Kuhajda FP, Bristow RE, Zhang H, Shih IeM.

J Oncol. 2010;2010:285191. doi: 10.1155/2010/285191. Epub 2010 May 19.

4.

Trophoblastic neoplasms express fatty acid synthase, which may be a therapeutic target via its inhibitor C93.

Ueda SM, Mao TL, Kuhajda FP, Vasoontara C, Giuntoli RL, Bristow RE, Kurman RJ, Shih IeM.

Am J Pathol. 2009 Dec;175(6):2618-24. doi: 10.2353/ajpath.2009.081162. Epub 2009 Nov 5.

5.

Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells.

Zhou W, Tu Y, Simpson PJ, Kuhajda FP.

Oncogene. 2009 Aug 20;28(33):2979-87. doi: 10.1038/onc.2009.160. Epub 2009 Jun 22.

PMID:
19543323
6.

AMP-activated protein kinase and human cancer: cancer metabolism revisited.

Kuhajda FP.

Int J Obes (Lond). 2008 Sep;32 Suppl 4:S36-41. doi: 10.1038/ijo.2008.121. Review.

PMID:
18719597
7.

Intraperitoneal injections of low doses of C75 elicit a behaviorally specific and vagal afferent-independent inhibition of eating in rats.

Mansouri A, Aja S, Moran TH, Ronnett G, Kuhajda FP, Arnold M, Geary N, Langhans W, Leonhardt M.

Am J Physiol Regul Integr Comp Physiol. 2008 Sep;295(3):R799-805. doi: 10.1152/ajpregu.90381.2008. Epub 2008 Jul 30.

8.

Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors.

Orita H, Coulter J, Tully E, Kuhajda FP, Gabrielson E.

Clin Cancer Res. 2008 Apr 15;14(8):2458-64. doi: 10.1158/1078-0432.CCR-07-4177.

9.

The obesity epidemic: pharmacological challenges.

Bloom SR, Kuhajda FP, Laher I, Pi-Sunyer X, Ronnett GV, Tan TM, Weigle DS.

Mol Interv. 2008 Apr;8(2):82-98. doi: 10.1124/mi.8.2.6. Review.

PMID:
18403653
10.

Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight.

Aja S, Landree LE, Kleman AM, Medghalchi SM, Vadlamudi A, McFadden JM, Aplasca A, Hyun J, Plummer E, Daniels K, Kemm M, Townsend CA, Thupari JN, Kuhajda FP, Moran TH, Ronnett GV.

Am J Physiol Regul Integr Comp Physiol. 2008 Feb;294(2):R352-61. Epub 2007 Dec 5.

11.

Selective inhibition of fatty acid synthase for lung cancer treatment.

Orita H, Coulter J, Lemmon C, Tully E, Vadlamudi A, Medghalchi SM, Kuhajda FP, Gabrielson E.

Clin Cancer Res. 2007 Dec 1;13(23):7139-45. Epub 2007 Dec 3.

12.

Modulation of carnitine palmitoyltransferase-1 for the treatment of obesity.

Kuhajda FP, Ronnett GV.

Curr Opin Investig Drugs. 2007 Apr;8(4):312-7. Review.

PMID:
17458181
13.

Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells.

Zhou W, Han WF, Landree LE, Thupari JN, Pinn ML, Bililign T, Kim EK, Vadlamudi A, Medghalchi SM, El Meskini R, Ronnett GV, Townsend CA, Kuhajda FP.

Cancer Res. 2007 Apr 1;67(7):2964-71.

14.

FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer.

Lee JS, Orita H, Gabrielson K, Alvey S, Hagemann RL, Kuhajda FP, Gabrielson E, Pomper MG.

Pharm Res. 2007 Jun;24(6):1202-7. Epub 2007 Apr 3.

PMID:
17404812
15.

Fatty acid synthase and cancer: new application of an old pathway.

Kuhajda FP.

Cancer Res. 2006 Jun 15;66(12):5977-80. Review.

16.

Intracerebroventricular C75 decreases meal frequency and reduces AgRP gene expression in rats.

Aja S, Bi S, Knipp SB, McFadden JM, Ronnett GV, Kuhajda FP, Moran TH.

Am J Physiol Regul Integr Comp Physiol. 2006 Jul;291(1):R148-54. Epub 2006 Feb 16.

17.

The connections between C75 and obesity drug-target pathways.

Kuhajda FP, Landree LE, Ronnett GV.

Trends Pharmacol Sci. 2005 Nov;26(11):541-4. Epub 2005 Sep 16.

PMID:
16169094
18.

Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells.

Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR.

Oncogene. 2005 May 19;24(22):3574-82.

PMID:
15806173
19.

Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase.

McFadden JM, Medghalchi SM, Thupari JN, Pinn ML, Vadlamudi A, Miller KI, Kuhajda FP, Townsend CA.

J Med Chem. 2005 Feb 24;48(4):946-61.

PMID:
15715465
20.

Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer.

Wang YY, Kuhajda FP, Li J, Finch TT, Cheng P, Koh C, Li T, Sokoll LJ, Chan DW.

J Exp Ther Oncol. 2004 Jul;4(2):101-10.

PMID:
15500005
21.

C75 alters central and peripheral gene expression to reduce food intake and increase energy expenditure.

Tu Y, Thupari JN, Kim EK, Pinn ML, Moran TH, Ronnett GV, Kuhajda FP.

Endocrinology. 2005 Jan;146(1):486-93. Epub 2004 Oct 21.

PMID:
15498887
22.

Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice.

Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP.

Oncogene. 2005 Jan 6;24(1):39-46.

PMID:
15489885
23.

C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase.

Kim EK, Miller I, Aja S, Landree LE, Pinn M, McFadden J, Kuhajda FP, Moran TH, Ronnett GV.

J Biol Chem. 2004 May 7;279(19):19970-6. Epub 2004 Mar 17.

24.

Chronic C75 treatment of diet-induced obese mice increases fat oxidation and reduces food intake to reduce adipose mass.

Thupari JN, Kim EK, Moran TH, Ronnett GV, Kuhajda FP.

Am J Physiol Endocrinol Metab. 2004 Jul;287(1):E97-E104. Epub 2004 Jan 21.

25.

C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism.

Landree LE, Hanlon AL, Strong DW, Rumbaugh G, Miller IM, Thupari JN, Connolly EC, Huganir RL, Richardson C, Witters LA, Kuhajda FP, Ronnett GV.

J Biol Chem. 2004 Jan 30;279(5):3817-27. Epub 2003 Nov 13.

26.

Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells.

Zhou W, Simpson PJ, McFadden JM, Townsend CA, Medghalchi SM, Vadlamudi A, Pinn ML, Ronnett GV, Kuhajda FP.

Cancer Res. 2003 Nov 1;63(21):7330-7.

27.

Expression of FAS within hypothalamic neurons: a model for decreased food intake after C75 treatment.

Kim EK, Miller I, Landree LE, Borisy-Rudin FF, Brown P, Tihan T, Townsend CA, Witters LA, Moran TH, Kuhajda FP, Ronnett GV.

Am J Physiol Endocrinol Metab. 2002 Nov;283(5):E867-79.

28.

A new model ELISA, based on two monoclonal antibodies, for quantification of fatty acid synthase.

Wang YY, Kuhajda FP, Cheng P, Chee WY, Li T, Helzlsouer KJ, Sokoll LJ, Chan DW.

J Immunoassay Immunochem. 2002;23(3):279-92.

PMID:
12227415
29.

C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity.

Thupari JN, Landree LE, Ronnett GV, Kuhajda FP.

Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502. Epub 2002 Jun 11.

30.

Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity.

Thupari JN, Pinn ML, Kuhajda FP.

Biochem Biophys Res Commun. 2001 Jul 13;285(2):217-23. Erratum in: Biochem Biophys Res Commun 2002 Jul 12;295(2):570.

PMID:
11444828
31.

Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients.

Wang Y, Kuhajda FP, Li JN, Pizer ES, Han WF, Sokoll LJ, Chan DW.

Cancer Lett. 2001 Jun 10;167(1):99-104.

PMID:
11323104
32.

Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis.

Parrish NM, Kuhajda FP, Heine HS, Bishai WR, Dick JD.

J Antimicrob Chemother. 1999 Feb;43(2):219-26.

PMID:
11252327
33.

Increased fatty acid synthase is a therapeutic target in mesothelioma.

Gabrielson EW, Pinn ML, Testa JR, Kuhajda FP.

Clin Cancer Res. 2001 Jan;7(1):153-7.

34.

Two-site ELISA for the quantitative determination of fatty acid synthase.

Wang Y, Kuhajda FP, Sokoll LJ, Chan DW.

Clin Chim Acta. 2001 Feb;304(1-2):107-15.

PMID:
11165205
35.

Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors.

Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, Kuhajda FP.

Science. 2000 Jun 30;288(5475):2379-81.

36.

Synthesis and antitumor activity of an inhibitor of fatty acid synthase.

Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA.

Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3450-4.

37.

Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology.

Kuhajda FP.

Nutrition. 2000 Mar;16(3):202-8. Review.

PMID:
10705076
38.

Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts.

Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, Townsend CA, Kuhajda FP.

Cancer Res. 2000 Jan 15;60(2):213-8.

39.

Insulin depletion leads to adipose-specific cell death in obese but not lean mice.

Loftus TM, Kuhajda FP, Lane MD.

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14168-72.

40.

Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma.

Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP.

Clin Cancer Res. 1997 Nov;3(11):2115-20.

41.

Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors.

Pizer ES, Lax SF, Kuhajda FP, Pasternack GR, Kurman RJ.

Cancer. 1998 Aug 1;83(3):528-37.

PMID:
9690546
42.

Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer.

Kadkol SS, Brody JR, Epstein JI, Kuhajda FP, Pasternack GR.

Prostate. 1998 Feb 15;34(3):231-7.

PMID:
9492852
43.

Obese gene expression at in vivo levels by fat pads derived from s.c. implanted 3T3-F442A preadipocytes.

Mandrup S, Loftus TM, MacDougald OA, Kuhajda FP, Lane MD.

Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4300-5.

44.

Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia.

Rashid A, Pizer ES, Moga M, Milgraum LZ, Zahurak M, Pasternack GR, Kuhajda FP, Hamilton SR.

Am J Pathol. 1997 Jan;150(1):201-8.

45.

Expression of fatty acid synthase is closely linked to proliferation and stromal decidualization in cycling endometrium.

Pizer ES, Kurman RJ, Pasternack GR, Kuhajda FP.

Int J Gynecol Pathol. 1997 Jan;16(1):45-51.

PMID:
8986532
46.

pp32 overexpression induces nuclear pleomorphism in rat prostatic carcinoma cells.

Gusev Y, Romantsev FE, Chen TT, Kayler AE, Kuhajda FP, Dooley WC, Pasternack GR.

Cell Prolif. 1996 Dec;29(12):643-53.

PMID:
9146727
47.

Structure of pp32, an acidic nuclear protein which inhibits oncogene-induced formation of transformed foci.

Chen TH, Brody JR, Romantsev FE, Yu JG, Kayler AE, Voneiff E, Kuhajda FP, Pasternack GR.

Mol Biol Cell. 1996 Dec;7(12):2045-56.

48.

Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells.

Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE, Kuhajda FP.

Cancer Res. 1996 Jun 15;56(12):2745-7.

49.

Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer.

Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR, Kuhajda FP.

Cancer Res. 1996 Mar 15;56(6):1189-93.

50.

Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells.

Pizer ES, Wood FD, Pasternack GR, Kuhajda FP.

Cancer Res. 1996 Feb 15;56(4):745-51.

Supplemental Content

Loading ...
Support Center